In the CY 2026 OPPS/ASC proposed rule we stated that the burden was minimized because the median payer-specific negotiated charge data that we proposed to collect on the Supplemental to Form CMS-2552-10: Weighted Median MAO Payer-Specific Negotiated Charge Data Worksheet is based on payer-specific data that would already be maintained by the hospital, the data from the MRF that hospitals are required to disclose under the hospital price transparency regulations at 45 CFR part 180
478 In 1995, high-dose IFN-2b became the first exogenous cytokine approved by FDA for the adjuvant treatment of advanced melanoma
Injection Basics Where : Subcutaneousbelly fat (2 inches from navel), thigh, or upper arm When : Same day each week, any time of day
Specifications Compounds: BPC-157 + GHK-Cu + TB-500 (co-formulated) Quantity: 70 mg total per vial, lyophilized powder Purity: 99%+ HPLC standard batch-specific Certificate of Analysis included for your exact lot Identity: confirmed by LC-MS Appearance: lyophilized powder Documentation: Every vial ships with access to a batch-specific Certificate of Analysis showing HPLC purity, mass-spectrometry identity confirmation, endotoxin, residual solvents, and water content for your exact lot